POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Fighting a dangerous virus with a Patient's own immune cells
Disease control Recruiting nowThis early-stage study is testing a new cell therapy for patients who develop a dangerous Epstein-Barr virus (EBV) infection after a stem cell transplant. The main goal is to find a safe dose of specially prepared immune cells designed to fight the virus. Researchers will also ch…
Matched conditions: POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Custom immune cells battle Post-Transplant virus in groundbreaking trial
Disease control Recruiting nowThis study tests a new cell therapy for patients who develop Epstein-Barr virus infections after receiving a stem cell transplant. Researchers are using genetically engineered immune cells designed to specifically target and eliminate virus-infected cells. The trial will evaluate…
Matched conditions: POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New hope for lymphoma patients who have run out of options
Disease control Recruiting nowThis study is testing whether a drug called loncastuximab tesirine can shrink tumors in adults with specific types of B-cell lymphoma that have come back or stopped responding to other treatments. The drug is designed to target cancer cells directly. Researchers will give the dru…
Matched conditions: POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New hope for transplant patients fighting cancer without harsh chemo
Disease control Recruiting nowThis study is testing whether combining two drugs—polatuzumab vedotin and rituximab—is safe and effective for treating a type of lymphoma that can develop after an organ or stem cell transplant. The goal is to control the cancer while avoiding the severe side effects of tradition…
Matched conditions: POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC